Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346077 | 0.90 | KMT2A (0.52) | KMT2AEPHX2POLBGAA | |
| SCHEMBL10015137 | 0.87 | KMT2A (0.49) | KMT2AEPHX2POLBGAA | |
| SCHEMBL3562349 | 0.82 | KMT2A (0.44) | KMT2AEPHX2POLBGAA | |
| SCHEMBL13349297 | 0.81 | KMT2A (0.50) | KMT2AEPHX2POLB | |
| SCHEMBL7872045 | 0.78 | HCAR3 (0.51) | KMT2AEPHX2 | |
| SCHEMBL31370084 | 0.75 | MDM4 (0.51) | KMT2A | |
| SCHEMBL12235815 | 0.74 | KMT2A (0.64) | KMT2AEPHX2GAA | |
| SCHEMBL178731 | 0.74 | KMT2A (0.57) | KMT2AEPHX2GAA | |
| SCHEMBL15948331 | 0.73 | KMT2A (0.53) | KMT2AEPHX2 | |
| SCHEMBL28552605 | 0.72 | EPHX2 (0.52) | KMT2AEPHX2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022178592-A1 | SOLID PHASE SYNTHESIS OF GLUTAMATE-UREA-LYSINE DERIVED (GUL DERIVED) PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETING CONJUGATES AND THEIR USE AS PRECURSORS FOR THERAPEUTIC AND / OR DIAGNOSTIC AGENTS | Telix International Pty Ltd (AU) | 2022-09-01 | — | — | WO | disclosed |